Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
AnGes said on September 4 that an investigator-initiated trial has been cleared in Canada for AV-001, a Tie2 receptor agonist it is codeveloping with Canadian biotech Vasomune Therapeutics, to prevent acute ischemic brain injury in hemodialysis patients. The study, approved…
To read the full story
Related Article
- AnGes/Vasomune’s ARDS Drug Gets Fast-Track Tag in US
May 30, 2024
- AnGes to Invest US$2 Million in Canada’s Vasomune
December 27, 2022
BUSINESS
- Tanabe to Wind Down NeuroDerm, Scrap EU Launch of Parkinson’s Drug
November 19, 2026
- Shionogi Narrows R&D Pipeline to 21 Priority Programs Across 3 Disease Areas
November 19, 2026
- Toho, SDF Hospital Conduct Emergency Drug Supply Drill
November 19, 2026
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026





